Epidemiological Characteristics of the COVID-19 Outbreak in a Secondary Hospital in Spain

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.

A user shared their experience with hair regrowth using supplements like NAC and DIM, and briefly using minoxidil with microneedling. They reported some improvement in hair density, but the community questioned the effectiveness compared to traditional treatments like finasteride.

A long-term finasteride user experienced side effects like sexual dysfunction, dry eyes, muscle weakness, and brain fog, which improved when they stopped the medication. They decided to stop finasteride again, questioning if maintaining hair was worth the negative impact on their well-being.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.